Entries by Ilona Margolis


Dallas, TX – June 15, 2024 – The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions.  Herein, the design of oligo-benzamides, efficient synthetic routes and preclinical studies showing their activity are detailed. Etira’s therapeutic compounds are based […]


Dallas, TX – May 14th, 2024 – Etira is pleased to announce the submission of the regulatory documents for approval of administration of its breakthrough oncology drug ERX-315 to the Human Research Ethics Committee (HREC) in Australia. This submission marks a significant milestone for EtiraRx and approval by HREC will enable the start of phase […]

ERX-208 potency in Ovarian Cancer

San Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity is dependent on LIPA expression. The data support the advancement of ERX-208 towards clinical trials in ovarian cancer.

Targeting LIPA in ovarian cancer

Dallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes of ovarian cancer- serous carcinoma, mucinous carcinoma, endometrioid adenocarcinoma and clear cell carcinoma. These […]

ERX-315 introduced at SABCS 2023

San Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms of endocrine therapy resistant breast cancer, including those driven by mutant estrogen receptor. Preclinical research, GMP […]

Independent validation of LIPA as a molecular target in TNBC

Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany. The authors conclude that LIPA-activity is a novel pharmacological target in TNBC therapy and argue for the implementation of LIPA inhibitors into personalized treatment […]

Positive preclinical data presented at AACR 2023

  Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented at The American Association for Cancer Research (AACR) annual meeting, demonstrate strong efficacy in multiple preclinical models both in vitro and in […]

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award

Dallas, Texas. April 17, 2023: We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of Medicine, who received the prestigious 2023 Presidential Distinguished Research Scholar Award. The Presidential Awards ceremony, held April 17 at the […]

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world’s largest breast cancer meetings driven by a diversity of thought leadership in breast oncology advancements […]